Downcoded

What Does 'Annual Review, No Changes' Actually Review?

CGS re-dated its MolDX repeat germline testing LCD effective November 12 and recorded the reason as annual review, no changes. The coverage text has not moved since June 2020. The document that decides which codes the once-per-lifetime limit applies to has been revised 21 times, and the biggest edit in its history pulled 16 codes off the list on a September afternoon in 2024 without stating a reason. Eleven of those codes carried $5.12 million of Part B money.


A Medicare contractor re-dated a coverage policy last Thursday and wrote down, as the reason, that nothing in it had changed.

That is accurate. L38288, the MolDX policy on repeat germline testing, took effect June 7, 2020 and now carries a revision effective date of November 12, 2026.

In between it has been revised six times. Four of those are annual reviews that changed nothing, and the other two moved section headings and reformatted the bibliography to AMA citation style.

Six revisions, 2,349 days, and not one word of the coverage text has moved.

So the policy is settled. The question is whether the thing it does to your claims is settled too.

"If the policy has not changed in six years, what has been changing?"

The Sentence That Does the Work

The whole policy runs on one line, and you should read it the way your MAC's edit engine reads it:

"Unit of Service (UOS) for any one specific germline DNA or RNA-based test is limited to one per lifetime."

One per lifetime. Not one per year, not one per episode, not one per ordering physician. The contractor's reasoning is that germline alleles do not change, so re-running the same test cannot produce new clinical information, and a service that produces no new information is not reasonable and necessary under 1862(a)(1)(A).

Then the policy hands you the compliance burden in the next breath:

"Providers should take reasonable measures to be aware of what if any germline testing a beneficiary has had prior to billing for germline testing."

The rest of this brief is for subscribers.

The impact tables, the code-level detail, and the rest of the analysis sit past this line.

$50 a month, or $500 a year.